BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study

Combined BRAF + MEK inhibition is FDA approved for BRAF V600E-mutant solid tumors except for colorectal cancer. However, beyond MAPK mediated resistance several other mechanisms of resistance such as activation of CRAF, ARAF, MET, P13K/AKT/mTOR pathway exist among other complex pathways. In the VEM-...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Blessie Elizabeth, Roszik, Jason, Janku, Filip, Hong, David S., Kato, Shumei, Naing, Aung, Piha-Paul, Sarina, Fu, Siqing, Tsimberidou, Apostolia, Cabanillas, Maria, Busaidy, Naifa Lamki, Javle, Milind, Byers, Lauren Averett, Heymach, John V., Meric-Bernstam, Funda, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938883/
https://www.ncbi.nlm.nih.gov/pubmed/36801912
http://dx.doi.org/10.1038/s41698-022-00341-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938883/
https://www.ncbi.nlm.nih.gov/pubmed/36801912
http://dx.doi.org/10.1038/s41698-022-00341-0

Ejemplares similares